|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01873 VIVA BIOTECH
Nominal 
2.410 -0.090 (-3.600%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,986,651 | -7.837% | 2,155,578 | 2,379,631 | 2,104,083 | 696,958 |
| Cost of Sales | (1,299,252) | -8.319% | (1,417,146) | (1,563,952) | (1,453,102) | (392,092) |
| Gross Profit | 687,399 | -6.911% | 738,432 | 815,679 | 650,981 | 304,866 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 78,106 | -49.451% | 154,515 | (363,539) | 181,738 | (443,136) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (95) | -- | 0 | 0 | 0 | (487) | |
| Profit / (Loss) before Taxation | 295,705 | -- | (55,953) | (459,165) | 347,701 | (356,210) | |
| Taxation | (73,718) | 68.164% | (43,837) | (45,055) | (47,141) | (22,660) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (54,693) | 235.067% | (16,323) | (24,255) | (13,014) | (8,010) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 167,294 | -- | (116,113) | (528,475) | 287,546 | (386,880) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 33,353 | -77.646% | 149,207 | 163,068 | 156,533 | 45,424 |
| Depreciation & Amortisation | 210,884 | 1.197% | 208,389 | 178,301 | 150,851 | 68,660 |
| Directors' Emoluments | 8,577 | -11.165% | 9,655 | 10,420 | 9,187 | 6,534 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified (Modified Report) | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 8.000 | -- | -6.000 | -28.000 | 15.000 | -25.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 2.277 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.175 | -- | 0.198 | 0.202 | 0.041 | 0.027 |
| NBV per share ($) | 1.783 | -- | 1.706 | 1.643 | 1.780 | 1.714 |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 121,805 |
| %Change | 4.278% |
| EPS / (LPS) | RMB 0.060 |
| NBV Per Share (¥) | RMB 1.829 |